<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05089747</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL21_0918</org_study_id>
    <nct_id>NCT05089747</nct_id>
  </id_info>
  <brief_title>CIRculating CANcer MAster-Protocol</brief_title>
  <acronym>CIRCAN MAP</acronym>
  <official_title>MAster Protocol Studying the Impact of Blood Biopsy on Screening, Diagnosis, Diagnostic and Follow-up of Solid Cancer in Adult</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This exploratory study will focus on the development of the analyses of blood biomarkers to&#xD;
      better understand the circulating biomarkers associated with cancer diagnosis, treatment&#xD;
      efficacy and progressive disease&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2046</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2046</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Liquid biopsy analyses</measure>
    <time_frame>Day 0</time_frame>
    <description>Extraction of circulating DNA or circulating RNA followed by a tumoral cells extraction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Standard technics of disease assessment</measure>
    <time_frame>Week 16</time_frame>
    <description>Genetic and transcriptomic explorations with immunofluorescence technique. Marking with specific markers of the tumor pathology. And enumaration of tumoral cells.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation between outcome 1 and outcome 2</measure>
    <time_frame>year 5</time_frame>
    <description>Building a biological collection of blood samples and following, diagnosis and prediction of adult solid cancer.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Adult With Solid Cancer</condition>
  <arm_group>
    <arm_group_label>Adult with solid cancer. No intervention.</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sampling for biomarker analysis (microRNA, circulating DNA…)</intervention_name>
    <description>From one to four blood samplings: at diagnosis, after the first cycle of treatment, end of treatment, progressive disease (or end of study).</description>
    <arm_group_label>Adult with solid cancer. No intervention.</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult with solid cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult (&gt;18y)&#xD;
&#xD;
          -  Owing a social security insurance&#xD;
&#xD;
          -  Any solid cancer diagnosed by histopathology or cytology&#xD;
&#xD;
          -  Patient with blood sampling required as per standard of care&#xD;
&#xD;
          -  Informed consent signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal to participate&#xD;
&#xD;
          -  No blood sampling required as per standard of care&#xD;
&#xD;
          -  Hemoglobin &lt; 7g/dl (&lt; 9g/dl if respiratory or cardiovascular disease history)&#xD;
&#xD;
          -  Heterologous blood transfusion in the last 48 hours&#xD;
&#xD;
          -  Weight under 20 kg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sebastian Couraud, MD, PhD</last_name>
    <phone>+33 4 478 864 401</phone>
    <email>sebastien.couraud@chu-lyon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hopital Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Sebastien COURAUD, MD, PhD</last_name>
      <phone>+33 4 478 864 401</phone>
      <email>sebastien.couraud@chu-lyon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 11, 2021</study_first_submitted>
  <study_first_submitted_qc>October 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>liquid biopsy</keyword>
  <keyword>solid cancer</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

